Market Capitalization (Millions $) |
227 |
Shares
Outstanding (Millions) |
54 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-49 |
Cash Flow (TTM) (Millions $) |
-27 |
Capital Exp. (TTM) (Millions $) |
0 |
Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals Inc is a biotechnology company focused on the development of therapeutics for neurodegenerative diseases. It was founded in 2008 and is headquartered in South San Francisco, California.
The company's main focus is on Alzheimer's disease and related neurological disorders. Acumen Pharmaceuticals aims to identify and develop innovative drugs that target the underlying causes of these diseases. Their research is centered on the discovery of small molecules that can effectively inhibit the accumulation and spread of pathological proteins in the brain, which are believed to be major contributors to neurodegeneration.
Acumen Pharmaceuticals utilizes advanced technologies and collaborations with leading academic institutions to support their drug discovery and development efforts. They aim to deliver disease-modifying treatments that can slow or halt the progression of neurodegenerative diseases like Alzheimer's, thereby improving the quality of life for affected individuals.
Overall, Acumen Pharmaceuticals Inc strives to make meaningful advancements in the field of neurodegenerative disease therapeutics through their innovative research and development initiatives.
Company Address: 427 Park St. Charlottesville 22902 VA
Company Phone Number: 297-1000 Stock Exchange / Ticker: NASDAQ ABOS
ABOS is expected to report next financial results on March 26, 2024. |
|
|